Product Performance, Big Money Lift Exelixis

EXEL discovers, develops, and commercializes new treatments for hard-to-treat cancers. Its product portfolio keeps growing as it focuses on more types of tumors. The company’s expanding treatment portfolio and ambitious growth plans position it for further expansion. And continually promising results on its treatments, including recently for renal cancer, show it could have the pipeline to keep shares rising.

On the earnings front, EXEL’s first-quarter 2025 report showed nearly $555 million in quarterly revenue with operating expenses of roughly $369 million. The company’s diluted per-share earnings were $0.55 on about $160 million of net income. EXEL has more than $1.6 billion on hand and raised its 2025 full-year revenue guidance to more than $2.1 billion for net product revenue and nearly $2.4 billion for total revenue.

It’s no wonder EXEL shares are up 31% this year – and they could rise more. MoneyFlows data shows how Big Money investors are once again betting heavily on the forward picture of the stock.

Exelixis Enjoys Big Money Support

Institutional volumes reveal plenty. In the last year, EXEL has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in EXEL shares. They reflect our proprietary inflow signal, pushing the stock higher:

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Exelixis.

Exelixis Fundamental Analysis

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, EXEL has had strong sales and earnings growth:

• 3-year sales growth rate (+14.8%)
• 3-year EPS growth rate (+55.9%)

Source: FactSet

Also, EPS is estimated to ramp higher this year by +15.7%.

Now it makes sense why the stock has been generating Big Money interest. EXEL has a track record of strong financial performance.

Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term.

Exelixis has been a top-rated stock at MoneyFlows. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s made the rare Outlier 20 report multiple times in the last year. The blue bars below show when EXEL was a top pick…sending shares higher:

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Exelixis Price Prediction

The EXEL action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in EXEL at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level and follow our free weekly MoneyFlows insights.